Dengue IgG ELISA Kit

Name: Dengue IgG ELISA Kit
SKU: DEIA508
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma (EDTA, lithium heparin or citrate plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

Enzyme immunoassay for the qualitative determination of IgG class antibodies against Dengue Virus in human serum or plasma (citrate, heparin).

Storage

Store the kit at 2 - 8°C. The opened reagents are stable up to the expiry date stated on the label when stored at 2 - 8°C.

Precision

Sensitivity

The sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. It is 100% (95 % confidence interval: 93.62 % - 100 %).

General Description

Dengue virus is a single-stranded RNA virus of about 50 nm in diameter belonging to the genus Flavivirus. Dengue and dengue hemorrhagic fever are caused by one of four closely related, but antigenically distinct, virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide crossprotective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. The viruses are transmitted by Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on human blood. Infection with dengue viruses produces a spectrum of clinical illness ranging from a nonspecific viral syndrome to severe and fatal hemorrhagic disease. It is primarily a disease of the tropics; its global distribution is comparable to that of malaria, and an estimated 2.5 billion people live in areas at risk for epidemic transmission. - Globally, there are an estimated 50 to 100 million cases of dengue fever and several hundred thousand cases of dengue hemorrhagic fever. 1. The case-fatality rate of DHF in most countries is about 5%; most fatal cases are among children and young adults. 2. Important risk factors for DHF include the strain and serotype of the infecting virus, as well as the age, immune status, and genetic predisposition of the patient. Risk groups: residents of or visitors to tropical urban areas.

Infection or presence of pathogen may be identified by: 1. PCR 2. Serology: e.g. ELISA

Citations

Have you cited DEIA508 in a publication? Let us know and earn a reward for your research.

Background

Dengue infection is a major public health problem and has been reported in most countries and regions. The incubation period for dengue virus infection is 4-7 days. Diseases range from asymptomatic infections and moderate febrile illness (dengue fever) to more severe manifestations such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DSS is the most severe clinical syndrome and also presents with coagulation abnormalities, plasma leakage and increased vascular fragility. Loss of body fluids due to increased capillary permeability leads to hypovolemic shock and multi-organ failure.

The pathogenesis of DENV infection is still being explored. The researchers propose that the body's immune response plays a key role in this, due to the fact that they found that DENV infection symptoms are most severe when the host immune system is activated and clears the virus. Most primary infections are usually asymptomatic or mildly symptomatic, and secondary dengue infections may result in severe clinical manifestations such as DSS. Individuals infected with a particular serotype are immunoprotected against re-infection with the same type of infection, but this immune-protection is less effective in the case of infections with other serotypes.

The pathogenesis of dengue is associated with a variety of viral and host factors such as nonstructural protein 1 (NS1) viral antigens, DENV genomic variants, subgenomic RNA, antibody-dependent enhancement (ADE), memory cross-reactive T cells, anti-DENV NS1 antibodies, and autoimmunity. In the acute phase of the disease, soluble secreted lipid particle NS1 (s-NS1) levels are high and correlate with disease severity. NS1 has been observed to be a major contributor to the disruption of endothelial cell monolayer integrity. It destroys the integrity of the endothelial cell monolayer by activating macrophages and human peripheral blood mononuclear cells (PBMCs) via TLR 4, which induces the production of inflammatory cytokines. NS1 also induces shedding of heparan sulfate proteoglycans, leading to disruption of the endothelial glycocalyx layer of human pulmonary vascular endothelial cells and to shedding of sialic acid from the cell surface. All these factors contribute to the increase in vascular permeability in response to the direct action of NS1 antigen.

Pathogenesis of dengue fever is associated with multiple viral and host factors Figure 1. Complex interplay of viral and host factors in pathogenesis of dengue virus infection
(Source: Bhatt P, et al. 2021)

References

1. Bhatt P, et al. Current Understanding of the Pathogenesis of Dengue Virus Infection. Curr Microbiol. 2021 Jan;78(1):17-32.
2. Khanam A, et al. Immune-Mediated Pathogenesis in Dengue Virus Infection. Viruses. 2022 Nov 21;14(11):2575.

Documents

pdf COA

pdf SDS

pdf Datasheet

Infectious Disease Test Kits and Positive Controls

QA & Reviews

Customer Reviews

References

Dengue virus NS1 secretion is regulated via importin-subunit β1 controlling expression of the chaperone GRp78 and targeted by the clinical drug ivermectin

mBio

Authors: Denolly S, Guo H, Martens M, Płaszczyca A, Scaturro P, Prasad V, Kongmanas K, Punyadee N, Songjaeng A, Mairiang D, Pichlmair A, Avirutnan P, Bartenschlager R.

Abstract

Dengue virus (DENV) is a major human pathogen that can cause hemorrhagic fever and shock syndrome. One important factor of DENV pathogenicity is non-structural protein 1 (NS1), a glycoprotein that is secreted from infected cells. Here we study the mode of action of the widely used drug ivermectin, used to treat parasitic infections and recently shown to lower NS1 blood levels in DENV-infected patients. We found that ivermectin blocks the nuclear transport of transcription factors required for the expression of chaperones that support the folding and secretion of glycoproteins, including NS1. Impairing nuclear transport of these transcription factors by ivermectin or depleting them from infected cells dampens NS1 folding and thus its secretion. These results reveal a novel mode of action of ivermectin that might apply to other flaviviruses as well.

Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults

N Engl J Med

Authors: Kallás EG, Cintra MAT, Moreira JA, Patiño EG, Braga PE, Tenório JCV, Infante V, Palacios R, de Lacerda MVG, Batista Pereira D, da Fonseca AJ, Gurgel RQ, Coelho IC, Fontes CJF, Marques ETA, Romero GAS, Teixeira MM, Siqueira AM, Barral AMP, Boaventura VS, Ramos F, Elias Júnior E, Cassio de Moraes J, Covas DT, Kalil J, Precioso AR, Whitehead SS, Esteves-Jaramillo A, Shekar T, Lee JJ, Macey J, Kelner SG, Coller BG, Boulos FC, Nogueira ML.

Abstract

Background: Butantan-Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed.

Methods: In an ongoing phase 3, double-blind trial in Brazil, we randomly assigned participants to receive Butantan-DV or placebo, with stratification according to age (2 to 6 years, 7 to 17 years, and 18 to 59 years); 5 years of follow-up is planned. The objectives of the trial were to evaluate overall vaccine efficacy against symptomatic, virologically confirmed dengue of any serotype occurring more than 28 days after vaccination (the primary efficacy end point), regardless of serostatus at baseline, and to describe safety up to day 21 (the primary safety end point). Here, vaccine efficacy was assessed on the basis of 2 years of follow-up for each participant, and safety as solicited vaccine-related adverse events reported up to day 21 after injection. Key secondary objectives were to assess vaccine efficacy among participants according to dengue serostatus at baseline and according to the dengue viral serotype; efficacy according to age was also assessed.

Results: Over a 3-year enrollment period, 16,235 participants received either Butantan-DV (10,259 participants) or placebo (5976 participants). The overall 2-year vaccine efficacy was 79.6% (95% confidence interval [CI], 70.0 to 86.3) - 73.6% (95% CI, 57.6 to 83.7) among participants with no evidence of previous dengue exposure and 89.2% (95% CI, 77.6 to 95.6) among those with a history of exposure. Vaccine efficacy was 80.1% (95% CI, 66.0 to 88.4) among participants 2 to 6 years of age, 77.8% (95% CI, 55.6 to 89.6) among those 7 to 17 years of age, and 90.0% (95% CI, 68.2 to 97.5) among those 18 to 59 years of age. Efficacy against DENV-1 was 89.5% (95% CI, 78.7 to 95.0) and against DENV-2 was 69.6% (95% CI, 50.8 to 81.5). DENV-3 and DENV-4 were not detected during the follow-up period. Solicited systemic vaccine- or placebo-related adverse events within 21 days after injection were more common with Butantan-DV than with placebo (58.3% of participants, vs. 45.6%).

Conclusions: A single dose of Butantan-DV prevented symptomatic DENV-1 and DENV-2, regardless of dengue serostatus at baseline, through 2 years of follow-up. (Funded by Instituto Butantan and others; DEN-03-IB ClinicalTrials.gov number, NCT02406729, and WHO ICTRP number, U1111-1168-8679.).